Sarcoidosis Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Foresee Pharmaceuticals, AI Therapeutics, Molecure, Xentria, Inc., Kinevant Sciences, Novartis, aTyr Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Sarcoidosis pipeline constitutes 15+ key companies continuously working towards developing 15+ Sarcoidosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Sarcoidosis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sarcoidosis Market.

The Sarcoidosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Sarcoidosis Pipeline Report: https://www.delveinsight.com/sample-request/sarcoidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Sarcoidosis treatment therapies with a considerable amount of success over the years.
• Sarcoidosis companies working in the treatment market are Foresee Pharmaceuticals, AI Therapeutics, Molecure, Xentria, Inc., Kinevant Sciences, Novartis, aTyr Pharma, and others, are developing therapies for the Sarcoidosis treatment
• Emerging Sarcoidosis therapies in the different phases of clinical trials are- FP-020, LAM001, OATD-01, XTMAB-16, Namilumab, CMK389, Efzofitimod, and others are expected to have a significant impact on the Sarcoidosis market in the coming years.
• In September 2022, aTyr Pharma initiated a multicenter, randomized, double-blind, placebo controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versusplacebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroid (OCS), with or without immunosuppressant therapy
• In August 2022, the Food and Drug Administration (FDA) has granted Fast Track designation to efzofitimod (ATYR1923) for treatment of pulmonary sarcoidosis. Efzofitimod has also received FDA orphan drug designation for the treatment of sarcoidosis..

Sarcoidosis Overview
The multisystem illness sarcoidosis, whose cause is uncertain, is typified by non-caseating granulomas in the organs. This disease primarily affects young individuals and is characterized by bilateral hilar lymphadenopathy and reticular opacities in the lungs.

Get a Free Sample PDF Report to know more about Sarcoidosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/sarcoidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Sarcoidosis Drugs Under Different Phases of Clinical Development Include:
• FP-020: Foresee Pharmaceuticals
• LAM001: AI Therapeutics
• OATD-01: Molecure
• XTMAB-16: Xentria, Inc.
• Namilumab: Kinevant Sciences
• CMK389: Novartis
• Efzofitimod: aTyr Pharma

Sarcoidosis Route of Administration
Sarcoidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous

Sarcoidosis Molecule Type
Sarcoidosis Products have been categorized under various Molecule types, such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Sarcoidosis Pipeline Therapeutics Assessment
• Sarcoidosis Assessment by Product Type
• Sarcoidosis By Stage and Product Type
• Sarcoidosis Assessment by Route of Administration
• Sarcoidosis By Stage and Route of Administration
• Sarcoidosis Assessment by Molecule Type
• Sarcoidosis by Stage and Molecule Type

DelveInsight's Sarcoidosis Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Sarcoidosis product details are provided in the report. Download the Sarcoidosis pipeline report to learn more about the emerging Sarcoidosis therapies at:
https://www.delveinsight.com/sample-request/sarcoidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Sarcoidosis Therapeutics Market include:
Key companies developing therapies for Sarcoidosis are - Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc, Antares Pharma Inc, Fresenius SE and Co. KGa, Horizon Therapeutics Pc, Apotex Inc, Azurity Pharmaceuticals Inc., Cadila Healthcare Ltd., Dr. Reddys Laboratories Ltd., Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd, Mallinckrodt Plc, Medexus Pharmaceuticals Inc, Merck and Co. Inc, Novartis AG, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Viatris Inc., Johnson and Johnson Inc., and others.

Sarcoidosis Pipeline Analysis:
The Sarcoidosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Sarcoidosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sarcoidosis Treatment.
• Sarcoidosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Sarcoidosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sarcoidosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Sarcoidosis drugs and therapies-
https://www.delveinsight.com/sample-request/sarcoidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Sarcoidosis Pipeline Market Drivers
• Strategic alliances between the Pharmaceutical companies and universities, extensive research undertaking and funding are some of the important factors that are fueling the Sarcoidosis Market.

Sarcoidosis Pipeline Market Barriers
• However, side-effects associated with the treatment of Sarcoidosis, lack of awareness among people in developing countries and other factors are creating obstacles in the Sarcoidosis Market growth.

Scope of Sarcoidosis Pipeline Drug Insight
• Coverage: Global
• Key Sarcoidosis Companies: Foresee Pharmaceuticals, AI Therapeutics, Molecure, Xentria, Inc., Kinevant Sciences, Novartis, aTyr Pharma, and others
• Key Sarcoidosis Therapies: FP-020, LAM001, OATD-01, XTMAB-16, Namilumab, CMK389, Efzofitimod, and others
• Sarcoidosis Therapeutic Assessment: Sarcoidosis current marketed and Sarcoidosis emerging therapies
• Sarcoidosis Market Dynamics: Sarcoidosis market drivers and Sarcoidosis market barriers

Request for Sample PDF Report for Sarcoidosis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/sarcoidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Sarcoidosis Report Introduction
2. Sarcoidosis Executive Summary
3. Sarcoidosis Overview
4. Sarcoidosis- Analytical Perspective In-depth Commercial Assessment
5. Sarcoidosis Pipeline Therapeutics
6. Sarcoidosis Late Stage Products (Phase II/III)
7. Sarcoidosis Mid Stage Products (Phase II)
8. Sarcoidosis Early Stage Products (Phase I)
9. Sarcoidosis Preclinical Stage Products
10. Sarcoidosis Therapeutics Assessment
11. Sarcoidosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Sarcoidosis Key Companies
14. Sarcoidosis Key Products
15. Sarcoidosis Unmet Needs
16 . Sarcoidosis Market Drivers and Barriers
17. Sarcoidosis Future Perspectives and Conclusion
18. Sarcoidosis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Sarcoidosis Market https://www.delveinsight.com/report-store/sarcoidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Sarcoidosis Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Sarcoidosis Epidemiology https://www.delveinsight.com/report-store/sarcoidosis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Sarcoidosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Protein Supplements Market
https://www.delveinsight.com/report-store/protein-supplements-market
Protein Supplements Market By Source (Animal-Based [Whey, Casein, Fish, Eggs, Others], Plant-Based [Soy, Rice, Pea, Spirulina, Others]), By Product Type (Protein Powders, Protein Bars, Ready-To-Drink, And Others), By Application (Sports Nutrition And Functional Foods), By Distribution Channel (Supermarkets And Hypermarkets, E-Commerce, Direct-To-Consumer, Others), by geography is estimated to register growth at a remarkable CAGR forecast during 2022-2027 owing to the growing consumer awareness of having a protein rich diet,

Proteomics Market
https://www.delveinsight.com/report-store/prostate-cancer-market-insight
Proteomics Market By Product & Services (Instrumentation Technology [Spectroscopy, Chromatography, Electrophoresis, Protein Microarrays, X-Ray Crystallography, And Other], Reagents & Consumables, And Software & Services), By Application (Clinical Diagnostics, Drug Discovery, And Others), By End-User (Hospitals, Clinical Laboratories, Pharmaceutical Companies, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2028.

Infrared Thermometer Market
https://www.delveinsight.com/report-store/infrared-thermometer-market
Infrared Thermometer Market By Product Type (Contact Thermometers And Non-Contact Thermometers), By End-User (Food And Beverage Industry, Electronic Industry, Healthcare Industry, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2028 owing to the growing need for robust temperature measuring devices in critical industries and rise in the number of infectious diseases across the globe.

Hemoglobinopathies Market
https://www.delveinsight.com/report-store/sport-nutrition-market
Hemoglobinopathies Market By Indication (Thalassemia, Sickle Cell Anaemia, And Others), By Treatment (Stem Cell Therapy, Blood Transfusion, Iron Chelation Therapy, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2027 owing to the increasing prevalence of various hemoglobin disorders and the increasing research & developmental activities concerning to the hemoglobinopathies across the globe

Sport Nutrition Market
https://www.delveinsight.com/report-store/sport-nutrition-market
The Sports Nutrition Market By Product Type (Sports Drinks And Sports Supplements), By Distribution Channels (Hypermarkets & Supermarkets, E-Commerce, And Others), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing inclination toward following healthy and active lifestyle and growing importance of sports nutrition among athletes and sportspersons.

Endodontic Devices Market
https://www.delveinsight.com/report-store/endodontic-devices-market
Endodontic Devices Market By Product Type (Instruments [Apex Locators, Endodontic Motors, Endodontic Scalers, Endodontic Lasers, Handpieces, Machine-Assisted Obturation Systems, And Others], Consumables [Obturation, Access Cavity Preparation, Shaping And Cleaning]), By End-User (Dental Hospitals, Dental Clinics, And Others), and by geography is estimated to register growth at a remarkable CAGR during the forecast period from 2023-2028 owing to the rising patient pool associated with dental disorders, poor oral health, leading to increased number of root canal treatments, the increasing population opting for dental aesthetics, among others across the globe.

Chemotherapy Drugs Market https://www.delveinsight.com/report-store/chemotherapy-drugs-market
Chemotherapy Drugs Market By Drug Class (Alkylating Agents, Mitotic Inhibitors, Antimetabolites, Topoisomerase Inhibitors, And Others), By Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, And Others), By Route Of Administration (Oral And Parenteral), by geography is estimated to register growth at a remarkable CAGR forecast during 2023-2028 owing to increasing prevalence of different cancer types and increasing pharmaceutical trials for chemotherapy drugs.

Connected Drug Delivery Devices Market
https://www.delveinsight.com/report-store/connected-drug-delivery-devices-market
Connected Drug Delivery Devices Market By Product (Connected Sensors [Connected Inhaler Sensors And Connectable Injection Sensors] And Integrated Connected Devices [Connected Inhaler Devices And Connected Injection Devices], By Technology (Bluetooth, Near-Field Communication (NFC), And Others), By End-User (Healthcare Providers And Homecare), And by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of chronic diseases such as diabetes and improving healthcare it infrastructure across the globe.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.